All In Biotech

Drug Trial Radar · NCT02935634

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)

Last checked: Nov 19, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

190

Actual

Start

Nov 29, 2016

Primary completion

May 11, 2022

Study completion May 11, 2022

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Clovis Oncology, Inc.
First posted
Oct 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.

Conditions

  • Advanced Gastric Cancer

Interventions

  • NivolumabBiological

    Specified dose on specified days

  • IpilimumabBiological

    Specified dose on specified days

  • RelatlimabBiological

    Specified dose on specified days

  • BMS-986205Biological

    Specified dose on specified days

  • RucaparibDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by InvestigatorTime frame: From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (up to approximately 65 months)
  2. Median Duration of Response (DOR)Time frame: From first dose to date of first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 65 months)
  3. Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 WeeksTime frame: 24 weeks after first dose

Locations

35 sites in 9 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Local Institution - 0020

    Duarte, California

  • University Of Colorado

    Aurora, Colorado

  • Local Institution - 0032

    New Haven, Connecticut

  • Local Institution - 0036

    Washington D.C., District of Columbia

  • UF Health Medical Oncology - Davis Cancer Pavilion

    Gainesville, Florida

  • Local Institution - 0038

    Jacksonville, Florida

  • Local Institution - 0006

    Baltimore, Maryland

  • Local Institution - 0017

    Rochester, Minnesota

  • Local Institution - 0003

    St Louis, Missouri

  • Local Institution - 0001

    Hackensack, New Jersey

  • Local Institution - 0007

    New York, New York

  • Local Institution - 0002

    Portland, Oregon

  • Local Institution - 0005

    Philadelphia, Pennsylvania

  • UPMC

    Pittsburgh, Pennsylvania

  • Local Institution - 0004

    Seattle, Washington

  • Local Institution

    Randwick, Australia

  • Local Institution - 0035

    Westmead, New South Wales, Australia

  • Local Institution - 0033

    Heidelberg, Victoria, Australia

  • Local Institution

    Edmonton, Alberta, Canada

  • Local Institution

    Vancouver, British Columbia, Canada

  • Local Institution

    Ottawa, Ontario, Canada

  • Local Institution - 0025

    Toronto, Ontario, Canada

  • Local Institution - 0021

    Toronto, Ontario, Canada

  • Local Institution - 0039

    Heidelberg, Germany

  • Local Institution - 0043

    Leipzig, Germany

  • Local Institution

    Ramat Gan, Israel

  • Local Institution

    Tel Aviv, Israel

  • IRCCS Istituto Nazionale Tumori Milano

    Milan, Italy

  • Local Institution - 0014

    Milan, Lombardy, Italy

  • Local Institution

    Amsterdam, Netherlands

  • Local Institution

    Utrecht, Netherlands

  • Local Institution - 0050

    Singapore, Singapore

  • Local Institution - 0042

    Zurich, Switzerland

  • Local Institution - 0041

    Chur, Graubünden (de), Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.